Skip to main content

Tak Paul Peter's Form 4 filing

Candel Therapeutics, Inc. (CADL) · filed Sep 11, 2026

Accession no.
0001873905-26-000002
Filed
Sep 11, 2026, 6:12 PM ET
Trade date
Sep 10-11, 2026
Filing delay
1 day
Rule 10b5-1 plan
Checked

This filing lists 3 non-derivative transactions and 1 derivative transaction. Open-market sales total $3.16M. It was filed 1 day after the trade.

Reporting owners

A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.

Reporting owners on this filing
OwnerRelationship to the company
Tak Paul PeterCIK 0001873905Director, Officer (Chief Executive Officer)

Non-derivative securities (Table I)

Acquisitions and disposals of common stock and similar shares, one row per line on the filing.

Non-derivative transactions
Trade dateSecurityTransactionSharesPriceValueShares afterOwnershipFlags
Sep 10, 2026Common StockMOption exerciseAcquired+125,000$1.55+$193,750393,566Direct
Sep 10, 2026Common StockSSaleDisposed−220,866$11.50−$2,539,892.74172,700Direct
Sep 11, 2026Common StockSSaleDisposed−59,379$10.46−$620,890.58113,321Direct

Derivative securities (Table II)

Options, warrants, restricted stock units and similar. Shares are the underlying shares; price and value are for the derivative itself, and the holding after is in derivative units.

Derivative transactions
Trade dateSecurityTransactionUnderlying sharesUnit priceValueHeld afterOwnershipFlags
Sep 10, 2026Common StockMOption exerciseDisposed−125,000$0.00$01,638,968Direct

Footnotes

Livermore does not store Form 4 footnotes. For price ranges, how indirect holdings are held and trading plan details, read the original on SEC EDGAR.

Read the original on SEC EDGAR (opens in a new tab)